NRAS | GenomeWeb

NRAS

The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.

Can Almost See It

Newsweek reports that cancer researchers are cautiously optimistic that they will soon be able to target mutant Ras.

One of the first projects between the firms will be to develop and commercialize a companion diagnostic for the MEK inhibitor binimetinib in NRAS-mutant melanoma.

The draft document, which includes recommendations on which molecular tests labs should perform, on what samples, and with what analytical specifications, is available for comment until April 22.

A Phase II study comparing front-line treatment with anti-EGFR drug Vectibix against anti-VEGF therapy Avastin in a genetically defined subset of metastatic colorectal cancer patients has yielded promising results in favor of the anti-EGFR agent.

EntroGen this week announced the availability of expanded colorectal cancer screening products.

Transgenomic announced this week that it has signed an agreement with Amgen to develop an IVD test to identify NRAS and KRAS mutated patients with advanced colorectal cancer using its RAScan kits.

Cepheid this week released an updated Xpert BCR-ABL Monitor test that incorporates lot-specific standardization using the World Health Organization BCR-ABL standards.

After missing the first-to-market opportunities with KRAS, both Merck KGaA and Amgen are strategically looking into additional gene markers, with the likely aim of being able to launch companion tests to their drugs that are more sensitive and accurate than the competition.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.